National medical device into the high-end market

WASHINGTON national medical device companies are seeking solutions to improve independent innovation capability and competitiveness of high-end market. April 23, the leading medical device companies in China Shandong Weigao Group to join hands with the Chinese Academy of Sciences, released a first batch of high-tech research plans to support the project, the project report had reached 122, which received funding support of Item 8 of the plan, involving polymer materials, blood purification materials, high-tech products such as orthopedic materials. Guide its second research project, the main R & D interests include medical materials, medical supplies, medical equipment and high-tech bio-medicine and other fields, will develop a high level of prices generous diagnosis treatment and products.

China Medical Device Industry Association statistics show that China's medical device manufacturers around 3000, but most small business scale, market power is limited, and in addition to individual enterprises, most are generic high-end medical equipment, improve the Lord, ECG, CT, MRI and other medical devices basically can not see the high-end domestic brands, multinational corporations monopoly over 80% domestic market share. In the ultrasound equipment, magnetic resonance imaging equipment, and other fields, the monopoly of multinational companies share even more than 90%. China Medical Device Industry Association, former vice president of Xerox Cheng said: "This is an absolute monopoly in fact, the result is high prices, but also aggravated the people 'doctor of your' problem."

Weigao Group has worked with Chinese Academy of Sciences DICP cooperation to break the monopoly of the German company, developed a recombinant protein immunoadsorption column, mainly used for dialysis or organ transplant rejection generated. Former domestic cost of each dialysis hemodialysis patients need more than 400 yuan, the annual average per patient more than 60,000 yuan; Viagra realize the localization of high costs can be reduced after each dialysis nearly 50%; China's 200 million people have kidney disease, Gateway products such as the use of high treatment, kidney dialysis each year for the country to save more than 600 million patients.

Accordance with the "Chinese Academy of Sciences - Granville High Group high-tech Research and Development Program" Framework for the development of arrangements for R & D each year 30 million yuan, of which Weigao Group invested 15 million yuan funds, representatives of the Office of Science and Technology of Shandong Province, Shandong Province invested 500 million CAS invested 500 million, Weihai municipal government invested 500 million in basic research, applied research and development, trial production, innovation platform, information and personnel exchanges, so as to carry out comprehensive cooperation.